San Francisco, 5
November 2018: The global atopic dermatitis drugs market size is expected to reach USD 6.41 billion by 2022,
according to a new report by Grand View Research, Inc., exhibiting a CAGR of
6.6% during the forecast period. Various factors such as emergence of novel
therapeutics and growing uptake of targeted therapies are stimulating the
growth of the market.
Eucrisa (Pfizer;
crisaborole ointment) was approved by the U.S. FDA for treatment of atopic
dermatitis (AD), in 2016. The drug is indicated for mild-to-moderate AD in
patients who are two years or older, meeting a key therapeutics need of the
market. Dupixent (Sanofi/Regeneron) was the first biologic to be launched in
2017 for management of AD. The drug is under clinical investigation for use in
pediatric population.
Several promising
candidates, especially biologics and small molecules, in pipeline are expected
to alter the AD therapeutic landscape post launch. Nemolizumab is anticipated
to be the first biologic (anti-IL-13) indicated for itching associated with
atopic dermatitis. Tralokinumab, an IL-13 inhibitor, is under evaluation for
safety and efficacy of treatment of moderate-to-severe AD.
Upcoming patent
expiration of key products, such as LEO Pharma’s Protopic, Mylan/Valeant’s
Elidel, and Bayer’s Desonate will result in generic penetration in therapeutic
space. However, novel therapeutics, such as Eucrisa and Dupixent, are likely to
gain traction over the forecast period and attain blockbuster status.
Underdeveloped and
unserved categories such as rarer subtypes and pediatric population offer
strong commercial opportunities. Drug companies are currently investigating
multiple treatment options in niche indications such as severe refractory
atopic dermatitis. Improving availability of new treatment modalities and
targeted approaches offer a promising future for the global atopic dermatitis
drugs market.
Access Research Report of Atopic Dermatitis Drugs Market @ www.grandviewresearch.com/industry-analysis/atopic-dermatitis-drugs-market
Further key findings from the report suggest:
· Corticosteroids dominated the drug class in
2016, owing to their indication as first-line therapeutics for atopic
dermatitis
· Recent launch of biologics and small
molecules such as Dupixent and Eucrisais likely to change the current
therapeutic scenario due to their target-oriented mechanism of action
· Calcineurin inhibitors are likely to
witness stifled growth because of adverse effects, non-specificity, and
development of resistance to chemical agents
· The U.S. was the leading regional market in
2016. It is posed to maintain its position through 2022, owing to burgeoning
disease burden, increasing treatment rate, and high drug cost
· The topical segment led the atopic
dermatitis drugs market in 2016, based on route of administration. Although the
segment is expected to continue leading the market through 2022, Dupixent’s
launch in 2017 marked the arrival of injectable. The new RoA is anticipated to
hold approximately 30.0% market share by 2022
· Bayer, LEO Pharma, Mylan, Pfizer, and
Sanofi are some of key players operating in the market
· Pfizer and Sanofi are anticipated to be
leaders in AD therapeutic space by 2022 due to growing adoption of targeted
therapies, such as Eucrisa and Dupixent
· Rarer subtypes, such as severe refractory
atopic dermatitis, have few treatment options available and lack a significant
pipeline. This field presents a strong commercial opportunity to drug
developers.
Browse more reports of this category by Grand View
Research at: www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has
segmented the global atopic dermatitis drugs market based on drug class, route
of administration, and region:
Atopic Dermatitis Drugs Class Outlook (Revenue, USD
Million, 2016 - 2022)
·
Corticosteroids
·
Calcineurin Inhibitors
·
PDE4 Inhibitors
·
Biologics
·
Others
Atopic Dermatitis Drugs Route of Administration
Outlook (Revenue, USD Million, 2016 - 2022)
·
Topical
·
Injectable
·
Oral
Atopic Dermatitis Drugs Regional Outlook (Revenue,
USD Million, 2016 - 2022)
·
U.S.
·
U.K.
·
Germany
·
Spain
·
France
·
Italy
·
Japan
Access Press Release of
Atopic Dermatitis Drugs Market@ www.grandviewresearch.com/press-release/global-atopic-dermatitis-drugs-market
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
No comments:
Post a Comment